This is the authors' abstract. We don't add key points for this paper.
The pooled PREEMPT results demonstrate that onabotulinumtoxinA is an effective prophylactic treatment for chronic migraine. OnabotulinumtoxinA resulted in significant improvements compared with placebo in multiple headache symptom measures, and significantly reduced headache-related disability and improved functioning, vitality, and overall health-related quality of life. Repeat treatments with onabotulinumtoxinA were safe and well tolerated.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Dodick et al. (2010) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: